Eterna Therapeutics

Eterna Therapeutics

Yahoo Finance • 23 hours ago

Three Biotechs Deliver Catalysts to Watch

DENVER, July 15, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s announcements from NeOnc Technologies (NASDAQ: NTHI), Ernexa Therapeutics(NASDAQ: ERNA), and VivoSim Labs(NASDAQ: VIVS) highlight three distinct pathways to potentia... Full story

Yahoo Finance • yesterday

PayPal jumps on reported takeover bid, Aehr Test soars

Investing.com -- U.S. stock index futures edged higher on Wednesday after softer inflation data and a strong start to the corporate earnings season boosted investor sentiment, with markets weighing whether resilient corporate profits can c... Full story

Yahoo Finance • 29 days ago

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today highlighted significant prog... Full story

Yahoo Finance • 2 months ago

Ernexa Reports 100% Survival And Complete Tumor Clearance In Ovarian Cancer Models; Stock Up

(RTTNews) - Ernexa Therapeutics (ERNA) unveiled breakthrough preclinical results showing that its lead cell therapy candidate, ERNA-101 achieved complete tumor elimination and 100% long-term survival when combined with PD-1 blockade in syn... Full story

Yahoo Finance • 2 months ago

Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models

CAMBRIDGE, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced new preclinical dat... Full story

Yahoo Finance • 3 months ago

Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split

Ernexa Therapeutics Inc. CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today ann... Full story

Yahoo Finance • 5 months ago

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasd... Full story

Yahoo Finance • 5 months ago

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, t... Full story

Yahoo Finance • 5 months ago

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune... Full story

Yahoo Finance • 7 months ago

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation o... Full story

Yahoo Finance • 7 months ago

Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of... Full story

Yahoo Finance • 8 months ago

Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials

The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1... Full story

Yahoo Finance • 8 months ago

Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform

Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune... Full story

Yahoo Finance • 9 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Cambium Networks Corp. 245,205,302 2.45 1.68 1.715 +1.097 Founder Group... Full story

Yahoo Finance • 9 months ago

Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation a... Full story

Yahoo Finance • 10 months ago

Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit

CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjee... Full story

Yahoo Finance • 10 months ago

Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented... Full story

Yahoo Finance • 10 months ago

Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference

CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featur... Full story

Yahoo Finance • last year

Ernexa regains Nasdaq compliance, continues trading on exchange

CAMBRIDGE, Mass. - Ernexa Therapeutics (NASDAQ:ERNA) has regained compliance with Nasdaq’s minimum bid price requirement for continued listing, the company announced Wednesday. The biotech firm, currently valued at $14.1 million, has seen... Full story

Yahoo Finance • last year

Ernexa Therapeutics changes independent auditor to Haskell & White

Ernexa Therapeutics Inc. (NASDAQ:ERNA), a small-cap biotech company currently valued at $13.54 million and showing signs of financial strain according to InvestingPro data, announced a change in its independent registered public accounting... Full story